Discounted Cash Flow
Procept Biorobotics Corp.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2020 | $7.7m | $-53.0m | $-48.6m | -687.0% | $-14.47 |
| 2021 | $34.5m (346.7%) | $-59.9m (-12.9%) | $-57.9m (-19.2%) | -173.6% (74.7%) | $-3.63 (74.9%) |
| 2022 | $75.0m (117.6%) | $-87.2m (-45.6%) | $-83.0m (-43.3%) | -116.2% (33.1%) | $-1.96 (46.0%) |
| 2023 | $136.2m (81.6%) | $-105.9m (-21.5%) | $-133.2m (-60.4%) | -77.8% (33.1%) | $-2.24 (-14.3%) |
| 2024 | $224.5m (64.8%) | $-91.4m (13.7%) | $-103.6m (22.2%) | -40.7% (47.6%) | $-1.75 (21.9%) |
| 2025 | $308.1m (37.2%) | $-95.6m (-4.5%) | $-58.3m (43.7%) | -31.0% (23.8%) | $-1.72 (1.7%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.